DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

NCT03110354 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

28

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated due to slow accrual.

Conditions

Leukemia, Myeloid, Acute
Leukemia, Lymphocytic, Acute

Interventions

DRUG: DS-3201b

Sponsor

Daiichi Sankyo